Close menu




May 27th, 2022 | 12:39 CEST

BioNTech, XPhyto Therapeutics, Snap Inc. - Tech falls, biotech gains

  • Biotechnology
  • Technology
  • biosensor
Photo credits: pixabay.com

The bearish market continues to slide. Tech companies like Snap Inc. saw share price declines of 31%. An alternative to high growth stocks are life science accelerators like XPhyto Therapeutics Corp. They are betting on the right partners and funds to bring biotech products to market faster than usual. While still with emergency approval, BioNTech is at the starting line for a Corona vaccine. Both German STIKO and partner Pfizer in the US are now targeting children for a COVID-19 vaccine.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , XPHYTO THERAPEUTICS | CA98421R1055 , SNAP INC. CL.A DL-_00001 | US83304A1060

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BioNTech - Business expansion through pediatric vaccines

    The Corona pandemic is becoming an endemic situation, yet there are new recommendations for vaccination. This week, for example, the Standing Committee on Vaccination (STIKO) decided that all children between the ages of 5 and 11 can be vaccinated with one dose of the BioNTech vaccine. STIKO also recommends that those who have recovered should continue to be vaccinated. The group of experts around the RKI assume that even multiple infections are insufficient to protect against infection or severe illness caused by viral variants.

    Fortunately, instead of recommendations and assumptions, there are still researchers who scientifically evaluate the degree of immunization. So far, three studies show that recovered individuals are better protected against re-infection. However, this refers only to the Delta variant.

    BioNTech is expressing entrepreneurial optimism based on the studies it has collected in-house. "Our COVID-19 vaccine has been studied in thousands of children and adolescents. We are pleased that our formulation for the youngest children, which we carefully selected to be one-tenth the adult dose strength, was well tolerated and elicited a strong immune response," said Albert Bourla, Pfizer's chairman and chief executive officer.

    "The study suggests that a low 3-inch dose of our vaccine, carefully selected based on tolerability data, provides infants with a high level of protection against recent COVID-19 strains," said Prof. Ugur Sahin, MD, CEO and co-founder of BioNTech. "We are preparing the appropriate documentation and expect to complete the submission process to the FDA this week, with submissions to the EMA and other regulatory agencies to follow in the coming weeks."

    XPhyto Therapeutics - Single-use oral biosensors at the point of care

    While antigen tests only moderately detect covid infection, biotech research is opening up some really passable solutions. Imagine you are out with colleagues or friends enjoying the nice weather and a BBQ. Two days later, you wake up with a cough, fever, headache, sore throat and aching limbs. Your antigen test shows nothing, but your symptoms speak a different language.

    That is where Canadian biotech company XPhyto Therapeutics Corp. comes in. XPhyto Therapeutics Corp. is a diversified life sciences accelerator focused on investing in next-generation drug delivery, diagnostics and new pharmaceutical entities. Accelerators provide acceleration in the development process by bringing together the right partners and funds to develop high-value products. Together with Vektor Pharma GmbH and 3a, XPhyto has developed rapid test products with near-term commercialization potential. In the pipeline are rapid tests for pathogen screening at the point of care. These include bacterial and viral infectious diseases such as stomatitis, peri-implantitis, periodontitis, group A streptococcus and influenza A.

    It allows either the patient at home or the treating physician in the office to achieve immediate certainty without poking around in the often hazy symptoms of colds. In collaboration with third-party European medical product marketing and distribution companies, XPhyto is now working to focus on and finalize its sales plan and prioritize its biosensor development pipeline to commercialize additional biosensor products for the European markets. For investors, this Company offers high potential to be in from the beginning.

    Snap Inc. - Price slide of 31%, has the bottom been reached?

    Investors in tech stocks must continue to be brave. Those who bet on growth stocks in previous years are currently being grounded. Between 2021 and 2022, the share price of social media service Snap Inc. regularly moved between EUR 65 and EUR 75. Today, it stands at around EUR 12. Since the end of April, "the macroeconomic environment has deteriorated further and faster than expected. As a result, we believe it is likely that we will be below the lower end of our Q2 2022 guidance range for revenue and adjusted EBITDA," the Company said in an official SEC filing.

    Looking at the Company's debt, it is clear how the problems are compounded. The Company has a debt level of more than 10 years. That means borrowed money will have to be paid back with higher interest rates than when inflation was lower. The stock fell 31% after this announcement.

    According to Reuters, CEO Evan Spiegel announced in a memo to his employees that the Company will cut back on recruitment this year. In addition, he cited a host of issues. "Like many companies, we continue to face rising inflation and interest rates, supply chain bottlenecks and labor disruptions, platform policy changes, the impact of the war in Ukraine, and much more," he wrote. What exactly Ukraine should have to do with Snap's growth is either known to insiders, or the Company should quickly develop new strategies to stabilize and further expand its growth. Investors should watch the bearish market in tech stocks calmly and implement their own money management tactics.

    Although Mark Zuckerberg has his eye on Snap Inc. with his company, Meta, the venture remains independent. However, it remains questionable whether funny filter faces and advertising revenue will continue to be a lucrative business model.


    With the STIKO recommendation and BioNTech partner Pfizer's efforts to have children worldwide vaccinated with one dose of the COVID-19 vaccine, a short-term growth spurt may be on the horizon. However, BioNTech needs to adapt the vaccine to common variants. Moderna, for example, is working on a vaccine for monkeypox. With biotech stocks, it often takes patience for products to reach the market because they are subject to scientific studies. Things move faster with bioscience accelerator XPhyto Therapeutics. The Canadian/German joint venture is working hard to commercialize oral biosensors for detecting pathogens such as influenza A. Currently, the slide in the share price of a tech stock like Snap Inc. seems somewhat symptomatic - quarterly targets were not met, investors punished the share, and there was a 31% price slide. Investors looking to get in should take a very close look at their business model and debt levels.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by Stefan Feulner on February 26th, 2024 | 07:15 CET

    Infineon, Saturn Oil + Gas, Block - Things are heating up here

    • Mining
    • Oil
    • GreenTech
    • chips
    • Technology

    Last week, all eyes were on chip giant Nvidia, which once again surprised Wall Street with a positive performance and a net profit increase of almost 770%. In Germany, Allianz also made headlines with a record profit and a significant dividend increase. In contrast, a report that could significantly impact the future of green technologies, with positive signals for the oil and gas industry, went somewhat unnoticed.

    Read

    Commented by Fabian Lorenz on February 20th, 2024 | 08:00 CET

    Sell Varta shares? Nel and Altech Advanced Materials with new opportunities

    • Technology
    • Batteries
    • renewableenergies

    The bad news for Varta seems to be unending. First, a cyber attack paralyzed the Company. Now, analysts are lowering their thumbs and recommending selling the share. Estimates for the years 2024 and 2025 have been lowered. As a result, Altech Advanced is increasingly becoming the German battery hopeful. Even though Altech's share price has declined significantly in recent months, the Company is on track operationally. The current year will be exciting. Things also remain exciting for hydrogen shares. While Nel and Plug Power & Co. still need to prove the future viability of their business models, they are receiving billions in support.

    Read

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

    Read